Biomedical Engineering Reference
In-Depth Information
[72] Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, et al. Genetic prodrug
activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide
gene expression. J Clin Oncol 1999;17:2180-9.
[73] Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster M, et al. Phase I
study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced
breast cancer or melanoma. Clin Cancer Res 2005;11:1512-20.
[74] Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. p53 mutations in breast
cancer. Cancer Res 1992;52:5291-8.
[75] Malkin D, Li FP, Strong LC, Fraumeni Jr JF, Nelson CE, Kim DH, et al. Germ line
p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
Science 1990;250:1233-8.
[76] Leach SD, Scatena CD, Keefer CJ, Goodman HA, Song SY, Yang L, et al. Negative regu-
lation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest
and apoptosis. Cancer Res 1998;58:3231-6.
[77] Parker LP, Wolf JK, Price JE. Adenoviral-mediated gene therapy with Ad5CMVp53 and
Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Ann Clin Lab Sci 2000;30:395-405.
[78] Slamon DJ, Clark GM. Amplification of c-erbB-2 and aggressive human breast tumors?
Science 1988;240:1795-8.
[79] Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the
HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
[80] Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, et al. The Ets protein PEA3 sup-
presses HER-2/neu over-expression and inhibits tumorigenesis. Nat Med 2000;6:189-95.
[81] Yan DH, Chang LS, Hung MC. Repressed expression of the HER-2/c-erbB-2 proto-onco-
gene by the adenovirus E1A gene products. Oncogene 1991;6:343-5.
[82] Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, et al. Cationic lipo-
some-mediated E1A gene transfer to human breast and ovarian cancer cells and its bio-
logic effects: a phase I clinical trial. J Clin Oncol 2001;19:3422-33.
[83] Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, et al. Phase
I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and
head and neck cancer. Clin Cancer Res 2001;7:1237-45.
[84] Nass SJ, Dickson RB. Defining a role for c-myc in breast tumorigenesis. Breast Cancer
Res Treat 1997;44:1-22.
[85] Popescu NC, Zimonjic DB. Chromosome-mediated alterations of the MYC gene in
human cancer. J Cell Mol Med 2002;6:151-9.
[86] Arteaga CL, Holt JT. Tissue-targeted antisense c-fos retroviral vector inhibits established
breast cancer xenografts in nude mice. Cancer Res 1996;56:1098-103.
[87] Holt JT, Arteaga CB, Robertson D, Moses HL. Gene therapy for the treatment of meta-
static breast cancer by in vivo transduction with breast-targeted retroviral vector express-
ing antisense c-fos RNA. Hum Gene Ther 1996;7:1367-80.
[88] Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, et al. Melanoma
differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene ther-
apy. Mol Med 2001;7:271-82.
[89] Luo J, Xia Q, Zhang R, Lv C, Zhang W, Wang Y, et al. Treatment of cancer with a novel
dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin
Cancer Res 2008;14:2450-6.
[90] Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral
injection of an adenovirus expressing interleukin 2 induces regression and immunity in a
murine breast cancer model. Proc Natl Acad Sci USA 1995;92:8522-6.
Search WWH ::




Custom Search